Duration of androgen deprivation therapy with salvage radiotherapy in patients with prostate cancer and biochemical recurrence after surgery: Initial recruitment data in the phase III URONCOR 06-24 trial
Loading...
Identifiers
Publication date
Authors
González San Segundo, C.
López-Campos, Fernando
Gómez Iturriaga, Alfonso
Santos, M.
Ocanto, Abrahams
Advisors
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
SDG
Metrics
Abstract
URONCOR 06-24 (NCT05781217) is a prospective, multicenter, randomized, open-label, phase III trial evaluating the impact on distant metastasis-free survival (MFS) of short-term (6 months) versus long-term (24 months) androgen deprivation therapy (ADT) in combination with salvage radiotherapy in high- and intermediate-risk patients after biochemical recurrence (BCR). A total of 534 men will be randomized to receive either 6 or 24 months of ADT. Stratification is based on risk group (intermediate vs high) and nodal status (pN0 vs pNx).
Description
UNESCO Subjects
Keywords
Bibliographic reference
González San Segundo, C., López-Campos, F., Gómez Iturriaga, A., Santos, M., Ocanto, A., Montezuma, L., Boladeras-Inglada, A. M., Glaria, L., Guardado, S., Rodríguez, A., Henríquez, I., Olivera, J., Duque-Santana, V., Garre, J., Moreno, S., Valero, J., Conde, A. J., Doval, A., Sancho, G., … Couñago, F. (2025). Duration of androgen deprivation therapy with salvage radiotherapy in patients with prostate cancer and biochemical recurrence after surgery: Initial recruitment data in the phase III URONCOR 06-24 trial. Actas Urológicas Españolas (English Edition), 49(7), 501823. https://doi.org/10.1016/j.acuroe.2025.501823